Hippocrates must be turning in his grave.
When Ezekiel Emanuel, MD, PhD, a pediatrician and health policy adviser int he federal Office of Management and Budget, argued in April that the Hippocrate Oath was one factor driving the “overuse” and – by extension – the cost of medical care he underscored, perhaps unwittingly, how far-ranging and emotionally charged the debate ablout healthcare reform is.
With a pipeline and the promise of greater use of their products ahead, biotechs are under more pressure than ever to prove value. Manufactures that align themselves with policy makers and payers through a CER framework may become a part of decision-making processes, rather than having to justify value from the outside looking in.
Read more at: